News & Media

Press release
Medivir to present at the ABGSC Life Science Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ABGSC Life Science Summit...

Read more
Press release Regulatory
Resolutions at the Annual General Meeting in Medivir on 5 May 2022

Medivir Aktiebolag (publ) held its annual shareholders’ meeting today on 5 May 2022. The annual general meeting was held by physical...

Read more
Press release Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2022

Momentum in several areas, not least the development of our cutting-edge project fostroxacitabine bralpamide January – March Financial summary for the...

Read more
Press release
Medivir to present at the Redeye Orphan Drugs Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Orphan Drugs Conference...

Read more
Press release
Medivir to participate at the Kempen Life Sciences Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will participate at the Kempen Life Sciences Conference,...

Read more
Press release Regulatory
Medivir 2021 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2021 now is available at the...

Read more
Press release Regulatory
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...

Read more
Press release
A subgroup analysis of Medivir´s phase II study of MIV-711 for osteoarthritis shows statistically significant reduction in OA pain

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an article entitled “Symptomatic and structural benefit of cathepsin K...

Read more
Press release
Medivir to present at the Erik Penser Bank Health Care Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that its new CEO Jens Lindberg will participate at the Erik...

Read more
Press release
MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2021

October – December Financial summary for the quarter Net turnover amounted to SEK 13.9 (1.5) million. The loss before interest, tax,...

Read more
Press release
Biomarker data from the fostroxacitabine bralpamide phase 1 study to be presented at the EASL Liver Cancer Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled “Liver biopsy biomarkers in a phase 1...

Read more
Press release
Medivir’s MIV-818 obtains the International Nonproprietary Name fostroxacitabine bralpamide

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the World Health Organization (WHO) has selected the International Nonproprietary...

Read more